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Objective: The Fifty-ninth Turkish Government announced an emergency action plan and em-
barked on a comprehensive health reform named “Health Transformation Program” (HTP) in
2003. This study investigated the effects of HTP on tuberculosis (TB) burden from 2003 to
2010 in Turkey.
Design: TB incidence, prevalence, mortality and case detection rates, treatment success and
direct observed treatment strategy (DOTS) applications rate, and contribution of these appli-
cations in the success of the TB war were retrospectively investigated.
Results: The annual decrease of incidence rate was 2.86 between 1995 and 2002, and 1.22 be-
tween and 2003 and 2010, (p < 0.05). The decrease of prevalence rate was 2.88 between 1995
and 2002 and 1.25 between 2003 and 2010 (p < 0.05). The annual declines in mortality were
0.44 between 1995 and 2002 and 0.22 between 2003 and 2010 (p < 0.005). The DOTS applica-
tion rate increased from 0% in 2003 to 98% in 2010. After the HTP treatment success rate of TB
at 85% of Turkey was firstly reached to 89% in 2005 and increased to 91% in 2007. Case detec-
tion rate of new pulmonary TB patients was 82% in 2005 and 81% in 2008 reaching the WHO
target for the first time with HTP.ity, School of Medicine, Department of Pulmonary Medicine, Besevler, Ankara, Turkey. Tel.: þ90 312
(Z. Yildirim).
3 Elsevier Ltd. All rights reserved.
3.09.011
2030 Z. Yildirim et al.Conclusion: A trend of reduced TB burden began in Turkey in 1997. As a result of the imple-
mentation of HTP beginning in 2003, the target treatment success and DOTS application rates
were achieved and progress has continued even in the face of the recent worldwide economic
crisis.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
One third of the world’s population is infected by Myco-
bacterium Tuberculosis (TB). According to the WHO Global
Tuberculosis Control report of 2011, 8.8 million each year
(range, 8.5 to 9.2 million) suffer from TB. Approximately
1.1 million of these patients (range, 0.9 to 1.2 million), and
0.35 million (range, 0.32 to 0.39 million) patients with ac-
quired immune deficiency syndrome would die due to TB
infection [1]. Turkey’s Ministry of Health reported a total of
17,400 registered patients in Turkey in 2009 [2].
Turkey experienced a serious TB epidemic at the
beginning of this century. TB was the leading cause of
death. This situation continued until the 1950s. The death
rate due to TB was around 200e250/100,000 in those years
[3,4]. Therefore, the fight against TB was begun in the first
years of the Republic of Turkey and is still continuing. TB
control has continued under the control and coordination of
this institution in collaboration with national and interna-
tional institutions [5]. Directly observed therapy strategy
(DOTS) implementation gained further momentum with the
extension of the program and started to get successful re-
sults. In 1991, WHO defined the targets of 70% detection of
sputum-smear positive cases and 85% treatment success
rate of these cases as an indicator of a successful TB control
programme. These targets were adopted and Stop TB
Strategy was implemented. Subsequently, the target pa-
rameters were further increased in the 2000s [6e9]. The
goals of the strategy are for prevalence and death rates to
be reduced by 50% relative to 1990 levels by 2015 and for TB
eradication all over the world by 2050 [8]. Turkey adopted
this strategy and is among 36 countries that have reached
this goal in recent years [5].
The Fifty-ninth Turkish Government announced an
emergency action plan and embarked on a comprehensive
reform of public health in 2003. This reform involved
serious changes in health services with a slogan “health for
everybody”. The main objectives of this program are the
maintenance of public health and, prevention of illness,
and thus improve the health status of the people and
reorganize the health sector in Turkey. With regard to the
planning and delivery of these services, priority has been
given to prevention, Primary Health Care services has been
strengthened and attention has been focused onto issues
like the proper functioning of public health services and the
efficient control of epidemic diseases [10].
After the implementation of the Health Transformation
Program (HTP), the most important advances in the
tuberculosis fight, performed under the patronage of
tuberculosis control department (TCD), were achieved by
the expansion of DOTS which is one of the main parts of
HTP. TCD is an institution affiliated with the ministry ofhealth. Responsibilities include the development of effec-
tive plans, programs and policies relevant to the tubercu-
losis war, taking all necessary measures to protect against
the spread of TB and to ensure the control and treatment of
TB, as well as education of patients, individuals and com-
munities about TB, and performing other responsibilities as
assigned by the Ministry of Health.
This study aimed to investigate the effect of HTP on TB
prevalence, incidence and mortality, case detection and
treatment success rate in Turkey.Method
Data collection
The data was obtained from TCD [2]. There were 198 active
TB dispensaries (TD) connected to TCD throughout Turkey
in 2010. Reporting of TB cases is mandatory in Turkey. All
TB cases diagnosed in private and public hospitals had to
report to the TB dispensaries to received TB drugs and for
contact examination. The surveillance system is based on
TB cases. Confirmed TB cases and contact examinations
have been carefully investigated by TB dispensaries. The
reporting of TB cases to TCD is undertaken by Local Health
Offices through filling in and sending of the standard forms
online to Ministry of Health. TCD officers analyse and pro-
cess the data and send them back to peripheral offices for
their records. These data are present in information system
of the Ministry of Health, as well.
These records were collected annually by the National
TB Surveillance Research organization. We analysed
these data and the study was approved by the Ministry of
Health.The success criteria
The targets established by WHO for TB control were used as
criteria for measuring the success of TB treatment and the
overall success of the fight against TB in Turkey during the
period of investigation [11]. TB incidence, prevalence,
mortality, case detection rate, treatment success, and
DOTS applications rate were studied and their overall ef-
fects of the TB war were determined. During the imple-
mentation of HTP, Stop TB Strategy was created under the
leadership of the WHO in 2006. Furthermore, the progresses
made toward achieving the aims of the Stop TB Strategy
were evaluated. Finally, the activities and changes in the
budget of TCD following the implementation of HTP as well
as innovations in the TB control program of this period were
investigated.
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Figure 1 A. The rates of TB incidence (A), TB prevalence (B) and TB death (C) between 1990 and 2010 have been significantly
decreased since 1997.
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Health politics and tuberculosis burden in Turkey 2033Statistics
Regression analysis was used to determine yearly changes in
investigated parameters. Pearson correlation analysis was
used to determine whether a relationship exists between
the budget of TCD and the incidence, prevalence and
mortality rates. A p-value of <0.05 was accepted as the
level of significance and SPSS 15.0 statistical analysis soft-
ware was used.Results
Incidence, prevalence and mortality rates
As shown in Fig. 1A and B, the rates of TB incidence and
prevalence in Turkey have declined for many years. Between
1997 and 2003 the incidence rate has decreased from 58/
100,000 to 37/100,000. After 2003, it was decreased from37/
100,000 to 28/100,000. The average annual decrease was
2.86 between 1995 and 2002, and 1.22 between 2003 and
2010, (p < 0.05). Similar changes were observed in preva-
lence. The amount of decreases in the average annual prev-
alence rate were 2.88 between 1995 and 2002 and 1.25
between 2003 and 2010 (p < 0.05). TB mortality has
decreased from9/100,000 in 1995 to 5/100,000 in 2003, and it
decreased from 5/100,000 in 2003 to 3/100,000 in 2010. The
annual declines in mortality were 0.44 between 1995 and
2002 and 0.22 between 2003 and 2010 (p < 0.005).Stop-TB targets (the reduction of TB prevalence
and deaths by 50% by 2015, in comparison with a
1990 baseline): Turkey’s position
While the TB prevalence rate in Turkey was 52/100,000 in
1990, it was reduced to 26/100,000 in 2006 and 24/100,000 in
2010. The targetof reducingTBprevalencebyhalf of the1990
ratewas, therefore, achieved in 2006 in Turkey after theHTP.
Also HTP application caused a reduction in the TB mor-
tality rate from 7.1/100,000 in 2002 to 3.3/100,000 in 2006
and 3/100,000 in 2010. Turkey reached the target preva-
lence rate in 2006.
Detection of new smear-positive pulmonary TB cases
The correct data related to detection of new semear-
posivite pulmonary TB cases and the treatment of smear
positive TB patents began to be obtained in 2002. Therefore
we con not perform a comparison between pre- and post-
HTP period. The target of WHO is detection of at least 70%
of new smear-positive pulmonary TB patients using bacte-
riological examination. In Turkey, in 2005 bacteriological
diagnosis was made in 82% of the new pulmonary TB pa-
tients, reaching this target for the first time with HTP. In
2008, this rate was 81%. As shown in Fig. 2C, this achieve-
ment has continued to the present. After 2008, WHOFigure 2 TB Incidence (A) and point TB prevalence (B) rates in T
between 2002 and 2010. (B) Case detection of new smear-positive
2008 WHO abandoned this calculation).abandoned this metric and, thus, it is not calculated in
subsequent years.
The treatment of smear-positive TB patients
Following the HTP application the success rate TB treat-
ment at 85% of Turkey was firstly reached to 89% in 2005
and increased to 91% in 2007. Turkey maintains the success
on the new smear-positive pulmonary TB patients.
DOTS practices in Turkey
The application of DOTS in Turkey was started as a pilot in
four tuberculosis dispensaries in 2003 with HTP, and was
extended throughout the rest of the country in June 2006.
The application of DOTSwas 50.9% in the second half of 2006,
and by 2009 had gradually increased to 96.6%. The DOTS
application rate increased from 0% in 2003 to 98% in 2010.
Budget of TCD
The budget of TCD has been increasing over the years, as
shown in Table 1. The budget for 2002 was 31,726,007 TL
and this figure increased by 58% to 53,440,922 TL in 2010.
As shown in Fig. 3A, B and C, we found highly statistically
significant negative correlations between budget figures
and TB incidence, TB prevalence and TB mortality rates. By
increasing the amount of budget, TB incidence (rZ 0.97,
p < 0.0001), TB prevalence (rZ 0.98, p < 0.0001) and TB
mortality (r Z 0.97, p < 0.0001) rates have decreased.
The share of DOTS within the TCD budget is depicted in
Table 2. Wholesale large amounts of drugs were purchased
in the first year of DOTS application in 2006. After that
DOTS expenditures were changed in subsequent years.
Discussion
This study showed that Turkey has achieved the Stop-TB
target (the reduction of TB prevalence and deaths by 50%
by 2015, in comparison with a 1990 baseline) after HTP
application. Also, following years of the HTP application,
the WHO’s target of the detection of new smear-positive
pulmonary TB cases at 70%, and the treatment of smear-
positive TB patients at 85% were achieved in 2005. DOTS
application was first begun in 2006 and the budget of TCD
has increased by 58% after HTP.
TB incidence has been decreased since 1997. This
decrement has been ongoing since 2003 when application of
the HTP was started. The incidence rate remained nearly
stationary between 2005 and 2006. The reason for this in-
crease cannot be fully explained; however, it may be
related to several factors, including an increase of contact
examinations, increased notification of TB patients and an
increase in diagnosis with improvement of health care in-
stitutions. We suggest that the TB patient number is rela-
tively increased due to the registered patients during these
years. Other reasons for the success might be increases inurkey were significantly lower than the WHO European Region
pulmonary TB cases depicted between 2002 and 2008. (After
Table 1 The changes of budget of TB Control Department
by years.
Years Budget of TB Control Department (TL)
1996 1,714,345
1997 3,907,172
1998 6,883,919
1999 11,397,131
2000 15,232,604
2001 21,227,451
2002 31,726,007
2003 37,830,924
2004 48,494,016
2005 52,211,874
2006 55,715,120
2007 52,979,439
2008 50,192,726
2009 53,483,757
2010 53,440,922
2034 Z. Yildirim et al.the budget figures, activities of TCD, political stability, and
improvement in the quality of health services. Most
importantly, it should be mentioned that the role of DOTS
treatment was expanded during this period throughout
almost all of Turkey. In addition, improvement of the gen-
eral health status in Turkey and increasing the number of
working health personnel are other parameters which play
a role in this success [12,13].
On the other hand, the ability of tuberculosis patients to
reach physicians was facilitated by HTP. Patients without
social security benefited from health services using social
assistance and other state funds. After the application of
HTP, the social security systems were combined and a So-
cial Security Administration was created, therefore facili-
tating access to all health service providers. With this
assurance, the patient can access both private and state
health care facilities. After the combination of social in-
surance (SSK) hospitals and public hospitals, patients had
access to a wider range of health care facilities and this
enabled previously undetected TB patients to be regis-
tered. Some TB patients that previously went undetected
due to limited access to health care facilities were regis-
tered under the new system, thereby increasing the
apparent number of TB cases in Turkey [12,13].
Despite the fact that, globally, TB control programs have
achieved some degree of success, the desired level of
achievement has not been reached, especially in Africa and
Asia. The main reasons for the lack of success of National
TB control programs are considered to be: inadequate
health care systems, economic failure and weak infra-
structure facilities, all of which result in a lack of diagnosis
and treatment of TB [14,15]. The main reason that coun-
tries with high rates of TB deaths are unable to achieve the
WHO’s targets is insufficient funding. Although the money
allocated would be doubled between 2002 and 2009 for the
control of TB in these countries, it is still an insufficient
amount [16]. The reasons behind the success of TB control
in Turkey are economic stability, governmental stability
and the gradual increase in money spent on the control of
tuberculosis in last decade. This increases in TB budgetresulted in the decrease of TB incidence, prevalence and
death rate in an almost one to one ratio (r: 0.97), (Fig. 3).
This increase in the budget became more prominent after
the implementation of the HTP.
The Chinese government has activated a tuberculosis
control program by using funding from the World Bank of
$58.2 million. While only 32% of TB cases could be diag-
nosed in the 1990s, with the implementation of a strong TB
control program, 80% of cases were diagnosed in 2005. This
program also emphasizes the importance of the need to
strengthen the public health system [17].
In a previous study determined what factors contribute
to differences in TB incidence rates among Chile, Colombia,
Bolivia and Peru. They proposed that comprehensive
implementation of the DOTS is the main factor explaining
the lower TB incidence rates in Colombia and Chile, even
after considering socio-economic factors [18]. Likewise, in
Turkey, DOTS have been implemented with success and
good results have been obtained.
Recently the HIV epidemic, especially in African coun-
tries, caused increases in TB incidence to the point of an
epidemic [19e22]. Thus, WHO needed development of na-
tional TB control programs in these areas. Up to the end of
1997, national TB control programs in Zambia were not suc-
cessful. Later on in this country, health care reformers and
anti-tuberculosis activists began cooperating and imple-
mented an effective TB control program. Therefore correct
TB diagnosis and treatmentwas possible and hope rose for TB
combat [23]. A similar example in Sudan has been experi-
enced. After the implementation of a TB control program,
the correct TB diagnosis rate increased from 16% in 1994 to
63% in 1996. And treatment success ratewere increased from
62% to 73% [24]. Owing to the DOTS, these countries have
overcome seemingly insurmountable obstacles, and become
a beacon of hope for the region. The treatment success rate
has increased, and mortality and resistance development
rates were decreased in many countries where DOTS has
been applied [25e28]. As mentioned above, the program has
been applied in 98% of our country.
The unpublished data obtained from Turkish Ministry of
Health revealed that there are 5224 HIVþ persons in Turkey.
Routine HIV testing in patients with TB was not performed in
Turkey until 2011. A circular was published by Ministry of
Health to conduct HIV testing of TB patients in 2011 and
found 21 TB patients who were also HIV positive in this year.
This initial data suggests that the association between HIV
and TB has not yet reached an important level.
One of the most important components of a healthcare
system is to improve health and to use the available funding
and resources in the most efficient way. Regardless of how
it was done, there are 6 basic components to achieving this
purpose: leadership/governance, health financing, health
service delivery, health work force, medical product/
technologies and health knowledge [29,30]. As mentioned
above, recently the tuberculosis fight in Turkey is based on
the Stop-TB Strategy guided by WHO. One of the six com-
ponents of the Stop-TB strategy is a fixed/reformed health
system. It is clear that an effective and sustainable tuber-
culosis control program is based on a strong public health
system. Such a system includes the strengthening of a na-
tional network of TB laboratories, the development of a
drug distribution system, efficient use of human labour and
Ar= -0.97, p<0.0001
The negative correlation between TB incidence and budget of TCD  
The negative correlation between TB mortality and budget of TCD 
C
r= -0.97, p<0.0001
The negative correlation between TB prevalence and budget of TCD 
B
r= -0.98, p<0.0001
Figure 3 A scatter graph for the budget of TCD and TB incidence (A), TB prevalence (B) and TB mortality rates (C). There are a
statistically significant negative correlations between budget figures and TB incidence (r Z 0.97, p < 0.0001), TB prevalence
(r Z 0.98, p < 0.0001) and TB mortality (r Z 0.97, p < 0.0001).
Health politics and tuberculosis burden in Turkey 2035the strengthening of primary health care as in the family
medicine system [29,30]. HTP mostly includes these pro-
posed suggestions to improve health and the TB fight in
Turkey.
As shown in Fig. 2A and B, comparing the point preva-
lence and incidence rates in Turkey and the WHO European
region, the values for Turkey are markedly lower than thatof the WHO European region. Fig. 2B clearly shows that, in
particular, the point prevalence rate in Turkey is signifi-
cantly lower than that of the WHO European Region. The
observed decrease in the point prevalence rate of the
WHO European region was 0.3% per year whereas it
was 1.82% per year in Turkey. The prevalence rate in
Turkey decreased from 51/100,000 in 1990 to 26/100,000 in
Table 2 DOTS expenditure within the TCD budget.
Years First-line drug expenses (TL) Second-line drug expenses (TL) Routine program management (TL) Total (TL)
2006 5,098,325.00 978,977,84 e 6,077,303.36
2007 2,638,226.78 Not buying drugs 629,618.19 3,267,844.97
2008 Not buying drugs 45,355.51 e 45,355.51
2009 1,806,810.00 1,325,960.00 537,990.00 3,670,760.00
2010 1,351,182.60 950,370.84 20,197.20 2,321,749.83
2036 Z. Yildirim et al.2006. Therefore, in 2006 Turkey had already achieved the
WHO Stop TB Strategy 2015 targeted prevalence rate
reduction.
As can be seen in an application performed in
Bangladesh, combining of non-governmental organizations,
the private sector and government forces in the struggle for
TB control resulted in an increase in success [31]. Similar
results were obtained in a previous practice in Kenya [32].
In this regard, it was concluded that inclusion of family
physicians in the implementation of DOTS treatment was
the right decision in Turkey.
TB drugs given free of charge is very important for the
success of a good TB control program. Recently a study was
conducted with funds provided by the government in the
Batibo region in Cameroon, where TB patients were treated
in a hospital. In this study, the DOTS conducted and the
drugs were distributed free of charge. They found that the
success of treatment, and diagnosis rates increased and
death rates significantly decreased [33]. Similar changes
were observed in our country.
The Turkish example and other successful countries such
as Cameroon and Kenya has suggested that the worldwide
control of TB can be achieved by increases of TB budgets,
governmental stability, proper treatment of TB cases by
DOTS, and increased research funding for development new
drugs and quick diagnostic methods.
The limitations of the study lie in the retrospective na-
ture of the work, the absence of some data such as
detection of new smear-positive pulmonary TB cases and
treatment success rate of smear positive pulmonary TB
patients before 2002. Therefore, we cannot compare these
data between pre and post HTP period. Additional studies
are needed to investigate the long term effect of the HTP
programme.
In conclusion, the prevalence, incidence and mortality
rates of TB have been decreasing in Turkey for decades.
HTP associated with the economic stabilization program of
Turkey have been continuing this achieved success when
dealing with the economic crisis in many countries. We also
suggest that the improvement in our registry system,
expansion of DOTS, strengthening of the laboratory
network, providing free TB drugs, increases in TCD budget,
restructuring of tuberculosis dispensaries, and strength-
ening international TB control efforts globally has contrib-
uted to the success of our tuberculosis control program. In
this way, the 2015 targets of the Stop-TB strategy were
achieved by 2006 and the achieved successes are
continuing. Obtained achievements give hope that Turkey’s
efforts will eliminate TB in future years. Additional studies
are needed to investigate the long term effect of the HTP
programme.Conflict of interest
This study was financed by the Republic of Turkey Ministry
of Health and World Bank.Acknowledgement
This study was financed by the Republic of Turkey Min-
istry of Health and World Bank. We thank Dr. Zekiye
C¸ELEB_I, Dr. Feral KARAMAN, Dr. Mustafa KOSDAK, Dr.
Seher MUSAONBAS‚IOGLU, Dr. Ays‚e Gu¨l YILDIRIM, Dr. Feral
KARAMAN, Hasan Go¨knul, employees of the Ministry of
Health TB Control Office of the Provincial Health Di-
rectorates and the other contributors for the data
collection and contribution to the preparation of the
report.References
[1] World Health Organization. Global tuberculosis control. WHO
report; 2011.
[2] Bozkurt H, Turkkanı MH, Musaonbasıoglu S, Yıldırım A,
Baykal F. Tu¨rkiye’de Verem Savası, 2011 Raporu. Ankara:
Verem Savası Dairesi Bas‚kanlıgı; 2011.
[3] Erkan ML. Tu¨berku¨lozun Tarihc¸esi, Du¨nyada ve Tu¨rkiye’deki
durumu. OMU Tıp Dergisi 1996;13:291e5.
[4] Yılmaz E. Anadolu’da verem panoraması. Tu¨rkiye Verem
Savas‚ı Dergisi 2010;1:9e14.
[5] Peks‚en S. U¨lkemizde veremle savas‚ mu¨cadelesi. Tu¨rkiye
Verem Savas‚ı Dergisi 2010;1:21e5.
[6] World Health Organization (WHO/HTM/TB/2008.393). World
Health Organization. Guidelines for tuberculosis treatment in
adults and children in national tuberculosis programme.
WHO/TB/91.161. Geneva, Switzerland: WHO; 1991.
[7] Jordan TS, Davies PD. Clinical tuberculosis and treatment
outcomes. Int J Tuberc Lung Dis 2010;14:683e8.
[8] The stop TB strategy [web site]. Geneva: World Health Orga-
nization; 2006http://www.who.int/tb/features_archive/
stop_tb_strategy/en/ [accessed 15.11.07].
[9] Caminero JA, de March P. Statements of ATS, CDC, and IDSA on
treatment of tuberculosis. Am J Respir Crit Care Med 2004;
169:316e7.
[10] Transformation in health. Ministry of Health of the Republic of
Turkey; December 2003.
[11] Compendium of indicators for monitoring and evaluating na-
tional tuberculosis programs. Geneva: MSH: Management Sci-
ences for Health. World Health Organization; 2004.
WHO/HTM/TB/2004.344.
[12] Akinci F, Mollahaliloglu S, Gu¨rso¨z H, Ogu¨cu¨ F. Assessment of
the Turkish health care system reforms: a stakeholder anal-
ysis. Health Policy 2012;107:21e30.
Health politics and tuberculosis burden in Turkey 2037[13] Tatar M, Mollahaliloglu S, Sahin B, Aydin S, Maresso A, Her-
na´ndez-Quevedo C. Turkey. Health system review. Health Syst
Transit 2011;13:1e186.
[14] Lo¨nnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K,
Glaziou P, Raviglione MC. Tuberculosis control and elimination
2010e50: cure, care, and social development. Lancet 2010;
375(9728):1814e29.
[15] Travis P, Bennett S, Haines A, et al. Overcoming health-
systems constraints to achieve the millennium development
goals. Lancet 2004;364:900e6.
[16] WHO. Global tuberculosis controlda short update to the 2009
report. WHO/HTM/TB/2009.426. Geneva: World Health Or-
ganization; 2009.
[17] Wang L, Liu J, Chin PD. Progress in tuberculosis control and
the evolving public-health system in China. Lancet 2007;369:
691e6.
[18] Sobero RA, Peabody JW. Tuberculosis control in Bolivia, Chile,
Colombia and Peru: why does incidence vary so much between
neighbours? Int J Tuberc Lung Dis 2006;10:1292e5.
[19] Harries AD, Zachariah R, Corbett EL, Lawn SD, Santos-Filho ET,
Chimzizi R, Harrington M, Maher D, Williams BG, De Cock KM.
The HIV-associated tuberculosis epidemicdwhen will we act?
Lancet 2010;375:1906e19.
[20] Corbett EL, Watt CJ, Walker N, Maher D, Williams BG,
Raviglione MC, Dye C. The growing burden of tuberculosis:
global trends and interactions with the HIV epidemic. Arch
Intern Med 2003;163:1009e21.
[21] Abdool Karim SS, Churchyard GJ, Abdool Karim Q, Lawn SD.
HIV infection and tuberculosis in South Africa: an urgent need
to escalate the public health response. Lancet 2009;
374(9693):921e33.
[22] Reid A, Scano F, Getahun H, Williams B, Dye C, Nunn P, et al.
Towards universal access to HIV/AIDS prevalence, treatment,
and care: the role of tuberculosis/HIV collaboration. Lancet
Infect Dis 2006;6:483e95.[23] Bosman MCJ. Health sector reform and tuberculosis control:
the case of Zambia. Int J Tuberc Lung Dıs 2000;4:606e14.
[24] El Sony AI, Baraka O, Enarson DO, Bjune G. Tuberculosis
control in Sudan against seemingly insurmountable odds. Int J
Tuberc Lung Dıs 2000;4:657e64.
[25] Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for
worldwide tuberculosis control under the WHO DOTS strategy.
Directly observed short-course therapy. Lancet 1998;
352(9144):1886e91.
[26] Yen YF, Rodwell TC, Yen MY, Shih HC, Hu BS, Li LH, Shie YH,
Chuang P, Garfein RS. DOT associated with reduced all-cause
mortality among tuberculosis patients in Taipei, Taiwan,
2006e2008. Int J Tuberc Lung Dis 2012;16:178e84.
[27] Bloss E, Chan PC, Cheng NW, Wang KF, Yang SL, Cegielsk P.
Increasing directly observed therapy related to improved
tuberculosis treatment outcomes in Taiwan. Int J Tuberc Lung
Dis 2012;16:462e7.
[28] Kumaresan JA, Ahsan Ali AK, Parkkali LM. Tuberculosis control
in Bangladesh: success of the DOTS strategy. Int J Tuberc Lung
Dis 1998;12:992e8.
[29] Tuberculosis and health systems. http://www.euro.who.int.
[30] Macroeconomics and health: investing in health for economic
development. Report of the commission on macroeconomics
and health. Geneva: World Health Organization; 2001.
[31] Kumaresan JA, de Colombani P, Karim E. Tuberculosis and
health sector reform in Bangladesh. Int J Tuberc Lung Dis
2000l;4:615e21.
[32] Hanson C, Kibuga D. Effective tuberculosis control and health
sector reforms in Kenya: challenges of an increasing tuber-
culosis burden and opportunities through reform. Int J Tuberc
Lung Dis 2000;4:627e32.
[33] Yumo HA, Mbanya D, Kuaban C, Neuhann F. Outcome assess-
ment of a global fund grant for tuberculosis control at the
district level in rural Cameroon. Int J Tuberc Lung Dis 2011;15:
352e7.
